More recently, it was reported that the growth-promoting cGMP signaling could be potentiated pharmacologically by treatment with sildenafil in murine and human melanoma cells, suggesting that possible skin adverse effects of PDE5 inhibitors should be better considered [268]. Here, PDE5A is linked to melanoma.